III. Aprotinin and cardiac surgery: A sorry tale of evidence misused

British Journal of Anaesthesia

Volumn 110, Issue 5, 2013, Pages 675-678

  McMullan, V ^a   Alston, R P ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; APROTININ; LYSINE DERIVATIVE; TRANEXAMIC ACID;

BLEEDING; BLOOD TRANSFUSION; BRAIN DISEASE; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS GRAFT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG MISUSE; DRUG SAFETY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART INFARCTION; HEART SURGERY; HUMAN; KIDNEY FAILURE; LICENCE; META ANALYSIS (TOPIC); OPEN HEART SURGERY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84876546995     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aet008     Document Type: Editorial

References (22)

1. Royston D, Taylor KM, Bidstrup BP, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987; 330: 1289-91
2. Fergusson D, Glass KC, Hutton B, Shapiro S. Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? Clin Trials 2005; 2: 218-29 (discussion 29-32)
3. U.S. Food and Drug Administration. Information for healthcare professionals: aprotinin injection (marketed as trasylol) 2010. Available from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm142726.htm (accessed 4 May 2012)
4. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Eng J Med 2006; 354: 353-65
5. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case- control comparison of aprotinin and tranexamic acid in hightransfusion- risk cardiac surgery. Transfusion 2006; 46: 327-8
6. Furnary AP, Wu YX, Hiratzka LF, Grunkemeier GL, Page US. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007; 116: I-127-I-133
7. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. J Am Med Assoc 2007; 297: 471-9
8. Trasylolw (aprotinin injection) briefing document 2007. Available from http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007- 4316b1-03-BAYER.pdf (accessed 18 August 2012)
9. Fergusson DA, Hébert PC. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Eng J Med 2008; 358: 2319-31
10. National Institute for Clinical Excellence. Reviewing and grading the evidence 2005. Available from http://www.nice.org.uk/niceMedia/pdf/GDM-Chapter7- 0305.pdf (accessed 4 May 2012)
11. The Committee of the Association of Cardiothoracic Anaesthetists. Statement on the use of aprotinin in cardiac surgery 2011. Available from http://www.acta.org.uk/store/docs/publications/ACTA-aprotinin-response-160306- 762321-31-08- 2011.pdf (accessed 8 July 2012)
12. FDA Cardiology and Renal Drugs Advisory Committee. Trasylolw (aprotinin injection) risk benefit review 2006. Available from http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4234S3- 01-Bayer.pdf (accessed 18 August 2012)
13. Health Canada. Final report-expert advisory panel on Trasylol (aprotinin) 2011. Available from http://hc-sc.gc.ca/dhp-mps/medeff/advise-consult/eap-gce- trasylol/final-rep-rap-eng.php (accessed 8 July 2012)
14. European Medicines Agency. European Medicines Agency recommends lifting suspension of aprotinin 2012. Available from http ://www.ema.europa.eu/docs/en- GB/document-library/Press-release/2012/02/WC500122914.pdf (accessed 4 May 2012)
15. Howell N, Senanayake E, Freemantle N, Pagano D. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 2012; 145: 234-40
16. Pagano D, Howell NJ, Freemantle N, et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 2008; 135: 495-502
17. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion (review). Cochrane Database Syst Rev 2011: CD001886
18. Takagi H, Manabe H, Kawai N, Goto S, Umemoto T. Aprotinin increases mortality as compared with tranexamic acid in cardiac surgery: a meta-analysis of randomized head-to-head trials. Interactive CardioVasc Thoracic Surg 2009; 9: 98-101
19. Ferraris VA, Brown JR, Despotis GJ, et al. 2011 Update to The Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice Guidelines. Ann Thorac Surg 2011; 91: 944-82
20. Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. Can Med Assoc J 2009; 180: 183-93
21. Health Canada. Health Canada decision on Trasylol (aprotinin) 2011. Available from http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/-2011/2011- 124-eng.php (accessed 23 October 2012)
22. European Medicines Agency. European Medicines Agency recommends lifting suspension of aprotinin 2012. Available from http://www.ema.europa.eu/docs/en- GB/document-library/Referrals-document/Antifibrinolytic-medicines/WC500122924. pdf (accessed 23, October 2012)